How do you interpret the results of the ACT II trial in terms of the choice between cisplatin and mitomycin in the treatment of anal cancers?

As you know, the ACT II conclusion was that a 5-FU/cisplatin regimen did not improve outcomes and had similar toxicities (less hematologic toxicities) when compared to the standard of care 5-FU/MMC. The RTOG 9811 trial demonstrated worse DFS/OS with induction followed by concurrent 5-FU/cisplatin. B...